

Dr. Bettina Ryll je ustanoviteljica Melanoma Patient Network Europe in je članica upravnega odbora Horizon Europe Cancer Mission.

Mrežo bolnikov z melanomom je ustanovila, potem ko je zaradi melanoma izgubila moža, kar je tudi razlog, da se je strokovno usmerila v klinične raziskave, ki v središče postavljajo pacienta, s poudarkom na inovativnih zasnovah raziskav in novih konceptih razvoja zdravil. V zadnjem času se osredotoča na pragmatične in trajnostne modele zdravstvenega varstva, ki zagotavljajo dostop do inovativnih terapij za bolnike z rakom in spodbujajo trajnostne inovacije.

Od leta 2019 je dr. Bettina Ryll članica upravnega odbora Horizon Europe Cancer Mission, kjer se ukvarja pretežno s priporočili za personalizirano medicino. Njena največja motivacija, tako zaradi osebne izkušnje kot zagovorniškega dela, je, da se znanstveni napredek čim hitreje spremeni v korist za bolnike. Zagovarja potrebo po uporabni znanosti v personalizirani medicini, da bi sistematično uskladili spodbude v kompleksnem okolju z več zainteresiranimi stranmi.

V letih 2015–2018 je dr. Ryll vodila delovno skupino zagovornikov pacientov ESMO in prvič je bila na čelu organizacije oseba, ki ni onkolog. PAWG je odgovoren za Patient Advocacy Track (Sledilnik zagovorništva pacientov) na letnih skupščinah ESMO, organizira tematske delavnice za širšo zagovorniško in medicinsko skupnost ter deluje kot svetovalka za dejavnosti ESMO.

Trenutno je članica fakultete ESMO za preiskovalno imuno-onkologijo.

Doktor Ryll je postala zdravnica na Free University of Berlin v Nemčiji, doktorat pa je dosegla s področja biomedicinskih znanosti na University College London v Veliki Britaniji.

Dr Bettina Ryll is the Founder of the Melanoma Patient Network Europe and member of the Horizon Europe Cancer Mission board.

Dr Ryll founded the Melanoma Patient Network Europe after losing her husband to melanoma and developed a special interest in patient-centric clinical research, in particular innovative trial designs and novel drug development concepts. Lately, her focus has moved to pragmatic and sustainable healthcare models ensuring access to innovative therapies for cancer patients and incentives for sustainable innovation.

Since 2019, Dr Ryll is member of the Horizon Europe Cancer Mission board and has been predominantly working on the recommendation on personalised medicine. Her particular motivation, largely influenced by her personal experience and advocacy work, is to see scientific advances rapidly turn into patient benefit. She argues for the need for implementation science in personalised medicine in order to systematically align incentives in a complex multi-stakeholder setting.

From 2015-2018, Dr Ryll chaired the ESMO Patient Advocates Working Group, the first time this position has been held by a non-oncologist. The PAWG is responsible for the Patient Advocacy Track at the annual ESMO meeting, organises workshops of interest to the wider advocacy and medical community and has an advisory function for ESMO activities.

Currently, she is member of the ESMO faculty for Investigational Immunooncology.

Dr Ryll holds a medical degree from the Free University of Berlin, Germany and a PhD in Biomedical Sciences from University College London, UK.